A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
RANGE IMPACT, INC.
RNGE
$75M
Mkt Cap
$0.70
-4.11%
RANGE IMPACT, INC. (RNGE) has a current P/E ratio of 17.5, compared to its historical median P/E of 8.3. The stock is currently considered Expensive based on its historical valuation range.
RANGE IMPACT, INC. (RNGE) has a 5-year average return on invested capital (ROIC) of 34.1%. This indicates strong capital allocation and a potential competitive advantage.
RANGE IMPACT, INC. (RNGE) has a market capitalization of $75M. It is classified as a small-cap stock.
RANGE IMPACT, INC. (RNGE) does not currently pay a regular dividend.
Based on historical P/E analysis, RANGE IMPACT, INC. (RNGE) appears expensive. The current P/E of 17.5 is 112% above its historical median of 8.3. The estimated fair value CAGR (P/E method) is 29.5%.
RANGE IMPACT, INC. (RNGE) operates in the Heavy Construction Other Than Bldg Const - Contractors industry, within the Industrials sector.
RANGE IMPACT, INC. (RNGE) generated $23 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Item 1. Business Our Company History We are a Nevada corporation, initially formed in June 2007 under the name “Legend Mining Inc.” for the purpose of engaging in mineral property exploration. The Company, however, was unable to keep its sole mineral claim in good standing due to insufficient funding, and its interest in that property terminated. Whereupon, in October 2011, the Company completed a merger with its wholly-owned subsidiary, Stevia First Corp., whereby the Company changed its name from “Legend Mining Inc.” to “Stevia First Corp.” and began focusing its business on the cultivation and harvest of stevia leaf and development of stevia products. As an outgrowth of its stevia leaf research, the Company commenced researching the development of cannabinoid pharmaceutical candidates known as cannabosides principally for the treatment of serious neurological and inflammatory disorders, a research activity we continued until the sale of our Graphium subsidiary.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 9.0M | 19M | 4.8M | - |
| Net Income | 19M | 19M | -9.8M | 3.1M | -1.1M | -4.4M |
| EPS | $0.18 | $0.18 | $-0.09 | $0.03 | $-0.02 | $-0.80 |
| Free Cash Flow | 23K | 23K | -1.6M | -2.8M | -6.4M | -3.6M |
| ROIC | -6.5% | 150.3% | -20.8% | 18.4% | -11.3% | - |
| Gross Margin | - | - | -9.8% | 32.2% | 28.8% | - |
| Debt/Equity | 0.08 | 0.08 | 4.32 | 0.94 | 1.77 | - |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | - | $0.00 |
| Operating Income | -1.7M | -1.7M | -2.2M | 2.2M | -1.1M | -3.7M |
| Operating Margin | 0.0% | - | -23.9% | 11.4% | -22.8% | - |
| ROE | 89.3% | 171.9% | -188.4% | 50.1% | -83.8% | - |
| Shares Outstanding | 106M | 106M | 109M | 104M | 54M | 5M |
| Metric | 2020 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 0 | 0 | N/A | 248K | N/A | N/A | N/A | N/A | 4.8M | 19M | 9.0M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | 39.8% | N/A | N/A | N/A | N/A | 28.8% | 32.2% | -9.8% | N/A | N/A |
| R&D | 736K | 575K | 1.1M | 613K | 894K | 1.9M | 1.7M | 1.0M | 471K | 459K | N/A | N/A | N/A |
| SG&A | 1.7M | 2.9M | 2.7M | 2.2M | 2.6M | 2.5M | 2.8M | 2.7M | 2.0M | 4.0M | 1.7M | 2.2M | 2.2M |
| EBIT | -2.5M | -3.6M | -3.8M | -2.7M | -3.5M | -4.4M | -4.6M | -3.7M | -1.1M | 2.2M | -2.2M | -1.7M | -1.7M |
| Op. Margin | N/A | N/A | N/A | -1104.0% | N/A | N/A | N/A | N/A | -22.8% | 11.4% | -23.9% | N/A | 0.0% |
| Net Income | -2.7M | -4.2M | -4.0M | -141K | -5.2M | -4.3M | -20M | -4.4M | -1.1M | 3.1M | -9.8M | 19M | 19M |
| Net Margin | N/A | N/A | N/A | -56.9% | N/A | N/A | N/A | N/A | -22.2% | 16.2% | -108.7% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 752K | 879K | 879K |
| Returns on Capital | |||||||||||||
| ROIC | N/M | -199.5% | N/M | N/M | N/M | N/M | -71.9% | N/A | -11.3% | 18.4% | -20.8% | 150.3% | -6.5% |
| ROE | N/A | N/A | N/A | 17.7% | -1394.2% | -1337.1% | -401.0% | N/A | -83.8% | 50.1% | -188.4% | 171.9% | 89.3% |
| ROA | -510.5% | -422.9% | -429.1% | -47.3% | -797.0% | -465.6% | -596.5% | N/A | -25.9% | 19.6% | -65.4% | 29.6% | 15.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -2.0M | -2.1M | -2.5M | -1.7M | -1.4M | -2.9M | -3.7M | -3.6M | -604K | 439K | -1.6M | 123K | 123K |
| Free Cash Flow | -2.0M | -2.1M | -2.5M | -1.7M | -1.4M | -2.9M | -3.7M | -3.6M | -6.4M | -2.8M | -1.6M | 23K | 23K |
| Owner Earnings | -2.8M | -3.4M | -2.8M | -2.0M | -2.1M | -3.9M | -4.4M | -4.2M | -1.6M | -2.2M | -1.7M | -267K | -267K |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.8M | 3.2M | 0 | 100K | 100K |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 592K | 2.3M | 90K | 78K | 78K |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5.2M | 949K | N/A | 22K | 22K |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 592K | 2.3M | 90K | 78K | 78K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 255.0% | N/A | N/A | 81.3% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 833K | 1.2M | 330K | 286K | 762K | 993K | 766K | 627K | 393K | 387K | 65K | 311K | 311K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 277K | 1.7M | 1.4M | 522K | 522K |
| Balance Sheet | |||||||||||||
| Net Debt | 188K | -1.4M | N/A | N/A | N/A | N/A | N/A | N/A | 4.8M | 6.8M | 3.4M | -310K | -310K |
| Cash & Equiv. | 392K | 1.4M | 390K | 95K | 1.2M | 656K | 6.0M | 2.4M | 442K | 2.2M | 167K | 2.1M | 2.1M |
| Long-Term Debt | 580K | 0 | N/A | N/A | N/A | N/A | N/A | N/A | 3.7M | 5.3M | 1.8M | 1.4M | 1.4M |
| Debt/Equity | -1.02 | 0.00 | -1.43 | -1.26 | 2.14 | 1.10 | 0.21 | N/A | 1.77 | 0.94 | 4.32 | 0.08 | 0.08 |
| Interest Coverage | -7.3 | -8.9 | -627.4 | -7553.1 | -3437.2 | N/A | -673.4 | N/A | -13.6 | 4.4 | -3.5 | -6.9 | -6.9 |
| Equity | -568K | -110K | -1.1M | -518K | 374K | 322K | 5.0M | N/A | 2.9M | 9.6M | 834K | 21M | 21M |
| Total Assets | 539K | 1.4M | 462K | 135K | 1.2M | 676K | 6.1M | N/A | 8.2M | 24M | 6.2M | 123M | 123M |
| Total Liabilities | 1.1M | 1.5M | 1.5M | 653K | 801K | 354K | 1.1M | 1.3M | 5.3M | 14M | 5.4M | 85M | 85M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 78M | 78M |
| Retained Earnings | -4.2M | -8.3M | -12M | -13M | -18M | -22M | -42M | -47M | -50M | -47M | -57M | -38M | -38M |
| Working Capital | 2K | -110K | N/A | N/A | N/A | N/A | N/A | N/A | -128K | 754K | 749K | -945K | -945K |
| Current Assets | 529K | 1.4M | N/A | N/A | N/A | 676K | 6.1M | 2.4M | 1.4M | 9.7M | 4.3M | 2.8M | 2.8M |
| Current Liabilities | 527K | 1.5M | N/A | N/A | N/A | N/A | N/A | N/A | 1.6M | 9.0M | 3.5M | 3.7M | 3.7M |
| Per Share Data | |||||||||||||
| EPS | -0.45 | -0.63 | -0.54 | -0.18 | -0.38 | -0.19 | -0.61 | -0.80 | -0.02 | 0.03 | -0.09 | 0.18 | 0.18 |
| Owner EPS | -0.46 | -0.51 | -0.38 | -2.51 | -0.16 | -0.17 | -0.13 | -0.77 | -0.03 | -0.02 | -0.02 | -0.00 | -0.00 |
| Book Value | -0.09 | -0.02 | -0.14 | -0.66 | 0.03 | 0.01 | 0.15 | N/A | 0.05 | 0.09 | 0.01 | 0.20 | 0.20 |
| Cash Flow/Share | -0.33 | -0.32 | -0.33 | -2.15 | -0.10 | -0.13 | -0.11 | -0.66 | -0.01 | 0.00 | -0.01 | 0.00 | 0.18 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 | N/A | 0.00 | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Shares Out. | 6.1M | 6.6M | 7.5M | 0.8M | 13.7M | 22.7M | 33.0M | 5.5M | 53.6M | 104.4M | 108.9M | 106.5M | 106.5M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 8.3 | N/A | N/A | 3.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 18.0 | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 69.3 | N/A | 0.3 | N/A | 3.3 | 2.7 | N/A | N/A | 3.5 |
| Price/Sales | N/A | N/A | N/A | 24.7 | N/A | N/A | N/A | N/A | 2.1 | 0.7 | N/A | N/A | N/A |
| FCF Yield | -8.0% | -9.5% | -74.1% | -9.2% | -5.3% | N/A | -277.6% | N/A | -66.5% | -10.9% | N/A | N/A | 0.0% |
| Market Cap | 25M | 23M | 3.4M | 18M | 26M | 0 | 1.3M | 0 | 9.6M | 26M | 0 | 0 | 75M |
| Avg. Price | 4.13 | 4.00 | 2.24 | 0.87 | 1.96 | 0.00 | 0.30 | 0.00 | 0.19 | 0.17 | 0.00 | 0.00 | 0.70 |
| Year-End Price | 4.50 | 3.80 | 0.50 | 2.58 | 1.89 | 0.00 | 0.04 | 0.00 | 0.18 | 0.33 | 0.00 | 0.00 | 0.70 |
RANGE IMPACT, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
RANGE IMPACT, INC. trades at 17.5x trailing earnings, compared to its 15-year median P/E of 8.3x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average ROIC is 34.1% with a gross margin of 17.1%. At current prices, the estimated annualized return to fair value is +29.5%.
RANGE IMPACT, INC. (RNGE) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
RANGE IMPACT, INC. (RNGE) reported earnings per share (EPS) of $0.18 in its most recent fiscal year.
RANGE IMPACT, INC. (RNGE) has a return on equity (ROE) of 171.9%. This indicates the company generates strong returns for shareholders.
RANGE IMPACT, INC. (RNGE) has a 5-year average gross margin of 17.1%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 14 years of financial data for RANGE IMPACT, INC. (RNGE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RANGE IMPACT, INC. (RNGE) has a book value per share of $0.20, based on its most recent annual SEC filing.